Først i human undersøgelse af CDR404 i HLA-A*02:01 Deltagere med MAGE-A4, der udtrykker solide tumorer
Fase 1, første-i-menneske-undersøgelse for at vurdere sikkerheden, tolerabiliteten og antitumoraktiviteten af CDR404 i HLA-A*02:01-deltagere med MAGE-A4-udtrykkende solide tumorer
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A*02:01 tissue marker and whose cancer is positive for MAGE-A4.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The CDR404-001 Phase 1 study will enrol patients with locally advanced, unresectable or metastatic tumors expressing MAGE-A4, which include advanced solid tumors, and will be conducted in multiple phases:
- To identify the maximum tolerated dose (MTD) and pharmacologically effective dose range (PEDR) for CDR404
- To assess preliminary evidence of anti-tumor activity of CDR404
- To characterise the pharmacokinetics of CDR404
- To characterise the immunogenicity of CDR404
- To assess translational biomarkers
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Antwerp, Belgien, 2650
- Universitair Ziekenhuis Antwerpen
-
Brussels, Belgien, 1070
- Institut Jules Bordet
-
Brussels, Belgien, 1200
- Cliniques Universitaires Saint-Luc, UCL Ouvain
-
Ghent, Belgien, 9000
- Universitair Ziekenhuis Gent
-
-
-
-
-
Copenhagen, Danmark, DK-2100
- Rigshospitalet
-
-
-
-
-
Glasgow, Det Forenede Kongerige
- The Beatson West of Scotland Cancer Center
-
London, Det Forenede Kongerige
- Guys and St Thomas' NHS Foundation Trust
-
-
London
-
Sutton, London, Det Forenede Kongerige, SM2 5PT
- Royal Marsden Hospital
-
-
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97213
- Providence Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19106
- Pennsylvania Hospital
-
-
-
-
-
Milan, Italien, 20089
- Istituto Clinico Humanitas
-
Milan, Italien, 20141
- Isituto Europeo di Oncologia (IEO)
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spanien, 08908
- Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO)
-
Madrid, Spanien, 28041
- Hospital 12 de Octubre
-
Madrid, Spanien, 28050
- START Madrid
-
Valencia, Spanien, 46026
- Hospital Universitari i Politecnic La Fe
-
Valencia, Spanien, 46026
- Instituto de Investigacion Sanitaria (INCLIVA)
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Provision of written informed consent
- HLA-A*02:01 positive
- MAGE-A4 positive tumor
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1
- Selected advanced solid tumors
- Relapsed from, refractory to, or intolerant of standard therapy
- Measurable disease per RECIST v1.1
- Adequate organ function
- If applicable, must agree to use highly effective contraception
Exclusion Criteria:
- Symptomatic or untreated central nervous system metastasis
- Inadequate washout from prior anticancer therapy
- Significant ongoing toxicity from prior anticancer treatment
- Recent surgery
- Clinically significant cardiac disease
- Active infection requiring systemic antibiotic treatment
- Human immunodeficiency virus (HIV) at risk of acquired immunodeficiency syndrome (AIDS)-related outcomes
- Active hepatitis B virus (HBV) or hepatitis C virus (HBC)
- Ongoing treatment with systemic steroids or other immunosuppressive therapies
- Significant secondary malignancy
- History of chronic or recurrent active autoimmune disease requiring treatment
- Uncontrolled intercurrent illness
- Pregnancy or lactation.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: CDR404
Dose escalation |
IV infusions |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Presence of dose limiting toxicities (DLTs)
Tidsramme: From first dose to DLT period (21 days)
|
per Protocol |
From first dose to DLT period (21 days)
|
|
Incidence and severity of (serious) adverse events ([S]AEs)
Tidsramme: From first dose to 90 days after the last dose
|
AEs, SAEs |
From first dose to 90 days after the last dose
|
|
Anti-tumor response: Overall Response Rate (ORR)
Tidsramme: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Disease control rate (DCR)
Tidsramme: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Duration of response (DOR)
Tidsramme: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Progression-free Survival (PFS)
Tidsramme: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Overall Survival (OS)
Tidsramme: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Maximum serum concentration of CDR404 (Cmax)
Tidsramme: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Time to maximum serum concentration of CDR404 (Tmax)
Tidsramme: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Trough serum concentration of CDR404 (Ctrough)
Tidsramme: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Half-life of CDR404 (t1/2)
Tidsramme: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Area under the CDR404 serum concentration over time curve (AUC0-T)
Tidsramme: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
to the end of the dosing interval following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Volume of CDR404 distribution (Vd)
Tidsramme: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Average serum concentration of CDR404 (Cavg)
Tidsramme: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Serum drug levels of CDR404 at steady state (CL)
Tidsramme: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Accumulation ratio of CDR404 (Rac)
Tidsramme: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Immunogenicity
Tidsramme: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
Incidence of detectable anti-CDR404 antibodies (ADAs) |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CDR404-001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .